Clinical Trials Logo

Activated B-cell Diffuse Large B-Cell Lymphoma (ABC DLBCL) clinical trials

View clinical trials related to Activated B-cell Diffuse Large B-Cell Lymphoma (ABC DLBCL).

Filter by:
  • None
  • Page 1

NCT ID: NCT02112526 Active, not recruiting - Clinical trials for Activated B-cell Diffuse Large B-Cell Lymphoma (ABC DLBCL)

Acalabrutinib (ACP-196), a Btk Inhibitor, for Treatment of de Novo Activated B-cell (ABC) Subtype of Diffuse Large B-Cell Lymphoma

Start date: August 7, 2014
Phase: Phase 1
Study type: Interventional

To characterize the safety profile of acalabrutinib in subjects with relapsed or refractory de Novo Activated B-cell (ABC) Subtype of Diffuse Large B-Cell Lymphoma (DLBCL).